Enclomiphene Citrate for Men 65 and Older: Transitioning to Adult Care

What Is Enclomiphene Citrate and Why Does It Matter in Older Men?

Enclomiphene citrate is the trans-isomer of clomiphene citrate, acting as a selective estrogen-receptor antagonist at the hypothalamic-pituitary axis. By blocking estrogen negative feedback, it raises gonadotropin-releasing hormone (GnRH) pulse amplitude, which drives LH and FSH secretion and therefore stimulates Leydig cell testosterone production. For men 65 and older, this mechanism is especially relevant because the dominant pathology of age-related hypogonadism is mixed: both primary (Leydig cell senescence) and secondary (reduced hypothalamic GnRH pulsatility) components coexist.

The Epidemiology of Low Testosterone After 65

Testosterone declines roughly 1 to 2 percent per year after age 30 in healthy men. The European Male Ageing Study (N=3,369) found that symptomatic androgen deficiency, defined by at least three sexual symptoms plus a total testosterone below 320 ng/dL, affected approximately 2.1 percent of men aged 40 to 79 overall, with prevalence rising steeply after age 70 [1]. Biochemical hypogonadism (testosterone <300 ng/dL without mandatory symptoms) is considerably more common, affecting up to 20 percent of men older than 60 in some cohort analyses [2].

Why Secondary Hypogonadism Persists Into Late Life

A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that a meaningful proportion of older men with low testosterone show inappropriately low or low-normal LH, consistent with secondary or mixed hypogonadism, making them theoretically responsive to upstream stimulation with an agent like enclomiphene [3]. This is the biological rationale for using enclomiphene rather than defaulting immediately to exogenous testosterone in every older man with symptomatic low T.

How Enclomiphene Differs from Clomiphene and Exogenous Testosterone

The Isomer Distinction

Clomiphene citrate is a roughly 60:40 mixture of the zuclomiphene (cis) and enclomiphene (trans) isomers. Zuclomiphene has a long half-life of 30 or more days and weak estrogenic agonist activity; enclomiphene has a half-life closer to 10 hours and pure antagonist activity at the hypothalamus. A Phase II crossover trial (N=159) published in the International Journal of Impotence Research found that enclomiphene 12.5 mg and 25 mg daily restored testosterone to normal range in men with secondary hypogonadism more consistently than clomiphene 50 mg every other day, with fewer mood complaints attributed to residual estrogenic activity [4].

Comparison With Exogenous Testosterone

Exogenous testosterone, whether delivered by intramuscular injection (testosterone cypionate 100 to 200 mg every 1 to 2 weeks), transdermal gel (testosterone 1.62%, 20.25 to 81 mg/day), or pellet implant, suppresses the HPG axis. LH and FSH fall toward zero within weeks. Enclomiphene does the opposite: LH and FSH rise, driving intratesticular testosterone production. The Testosterone Trials (TTrials, N=788 men, mean age 72) established that exogenous testosterone gel (1%, titrated to achieve serum testosterone 500 to 1,000 ng/dL) improves sexual function and bone mineral density in symptomatic older men [5]. Enclomiphene has not been studied in a comparable geriatric-specific randomized controlled trial, which is a genuine gap.

Enclomiphene in Secondary Hypogonadism: Trial Evidence

Key Phase II and Phase III Data

Repros Therapeutics conducted the ZA-301 and ZA-302 Phase III trials of enclomiphene in men with secondary hypogonadism (total testosterone <300 ng/dL, BMI 25 to 42, age 18 to 60). In ZA-301 (N=354), enclomiphene 12.5 mg and 25 mg daily raised mean morning testosterone from roughly 220 ng/dL at baseline to above 400 ng/dL at 12 weeks, compared with modest decline in the placebo arm [6]. Critically, the enrolled population skewed younger, with a mean age in the mid-30s. Men 65 and older were largely excluded.

What the Data Say About Older Respondents

A subgroup analysis from the ZA-303 open-label extension suggested that men with baseline LH below 9 IU/L responded most robustly to enclomiphene, regardless of age. Published case series and retrospective clinic data (including a 2022 series of 48 men, mean age 61, range 55 to 73, treated at a urology practice) found that roughly 70 percent of men with confirmed secondary hypogonadism achieved total testosterone above 300 ng/dL after 12 weeks at 12.5 mg daily [7]. Response rates appeared lower in men with higher baseline LH, consistent with predominant primary hypogonadism, which is more common as men age.

A Decision Framework for Patient Selection in Men 65 and Older

Before starting enclomiphene in a geriatric patient, clinicians should confirm secondary or mixed hypogonadism biochemically. A practical three-step screen:

1. Obtain two morning total testosterone levels (drawn before 10 AM on separate days). Both must be below 300 ng/dL.
2. Check LH and FSH. LH <9 IU/L with low testosterone confirms secondary etiology. LH above 12 IU/L suggests primary Leydig cell failure; enclomiphene is unlikely to provide meaningful benefit.
3. Exclude reversible causes first: opioid use (opioid-induced hypogonadism affects up to 70 percent of men on chronic opioids [8]), hyperprolactinemia, hemochromatosis, and hypothyroidism.

Transitioning Geriatric Patients to Adult Care Protocols

Many men older than 65 encountered their first testosterone evaluation in a general adult medicine or urology setting, sometimes decades earlier. When they transition to a hormone-focused or telehealth-based care model, the transition itself carries specific clinical responsibilities.

Reconciling Prior Therapy

Some men arrive having used exogenous testosterone for years. Abrupt discontinuation causes a symptomatic hypogonadal trough while the HPG axis recovers, a process that may take 3 to 6 months or longer in older men whose GnRH pulsatility is already blunted [9]. A structured washout protocol, tapering testosterone dose over 6 to 8 weeks while introducing enclomiphene at 6.25 mg daily, then uptitrating to 12.5 mg after confirming LH response, is used in clinical practice, though no randomized trial in geriatric men has validated this specific approach.

Updating the Comorbidity Profile

A man who was 50 when he started testosterone may now be 68, with new-onset atrial fibrillation, prostate cancer surveillance, or polycythemia. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism explicitly states, "We suggest against offering testosterone therapy to men who are actively trying to father children or those with an untreated pituitary or hypothalamic mass, uncontrolled heart failure, a hematocrit greater than 50%, or untreated obstructive sleep apnea" [10]. Enclomiphene avoids some of those contraindications by not delivering exogenous androgen, but PSA elevation risk and polycythemia risk from any testosterone elevation still apply.

Polypharmacy Interactions

Men 65 and older take an average of 5.8 prescription medications simultaneously [11]. Enclomiphene is metabolized primarily by CYP3A4. Concurrent use of CYP3A4 inhibitors (clarithromycin, fluconazole, diltiazem) may increase enclomiphene exposure; CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may reduce it. No dedicated drug-interaction pharmacokinetic study in older adults has been published, so clinical vigilance for unexpected hormonal fluctuation is necessary when co-medications change.

Dosing Considerations in Men 65 and Older

Standard adult dosing in clinical trials was 12.5 mg or 25 mg orally once daily. A starting dose of 6.25 mg in men 65 and older is a clinically conservative approach that allows assessment of tolerability before uptitration.

Pharmacokinetic Aging Effects

Hepatic CYP3A4 activity declines with age, oral bioavailability of many drugs increases as first-pass metabolism falls, and renal clearance of active metabolites slows. No published pharmacokinetic study has characterized enclomiphene disposition specifically in men older than 65. Extrapolating from general geriatric pharmacokinetic principles, a longer half-life and higher peak concentration at a given dose are plausible. The clinical implication is that titration should be slower, and the interval between dose increases should be at least 6 weeks rather than the 4 weeks used in younger-cohort trials.

Target Testosterone Range

The Endocrine Society guideline targets a morning testosterone of 400 to 700 ng/dL when treating hypogonadism [10]. Aiming for the lower half of that range (400 to 550 ng/dL) in men older than 65 is a prudent approach, balancing symptomatic benefit against the cardiovascular and polycythemic risks that increase with higher androgen levels.

Safety Profile and Geriatric-Specific Concerns

Visual Symptoms

Clomiphene citrate carries an FDA-labeled warning for visual disturbances, including blurred vision and photopsia. Enclomiphene, as the pure trans-isomer, has a lower theoretical risk because zuclomiphene accumulation drives most clomiphene-related ocular adverse events. Phase III trial data showed visual symptoms in fewer than 2 percent of enclomiphene-treated men at 12.5 mg [6]. For a geriatric patient with pre-existing age-related macular degeneration or diabetic retinopathy, baseline ophthalmologic documentation is advisable before starting therapy.

Cardiovascular Risk

The TRAVERSE trial (N=5,246, mean age 65.6 years) found that testosterone replacement therapy did not increase major adverse cardiovascular events (MACE) compared with placebo over a mean follow-up of 22 months (HR 0.96, 95% CI 0.78 to 1.17) [12], partially resolving prior uncertainty about TRT and cardiovascular risk. Enclomiphene has not been evaluated in a cardiovascular outcomes trial. Because it raises endogenous testosterone rather than delivering exogenous hormone, some clinicians consider the cardiovascular risk profile potentially more favorable, but this remains speculative without dedicated trial evidence.

Hematocrit and Erythrocytosis

Erythrocytosis (hematocrit above 52%) is the most common adverse effect of testosterone therapy, occurring in 3 to 18 percent of treated men in the TTrials [5]. Enclomiphene raises testosterone to lower absolute levels than high-dose TRT protocols in most patients, but erythrocytosis can still occur. Hematocrit should be checked at baseline and every 3 months for the first year, then every 6 months if stable.

Bone Health Intersection

Low testosterone in older men contributes to bone loss. The TTrials bone sub-study (N=211) found that testosterone gel significantly increased vertebral bone mineral density (3.5% increase vs. 1.0% for placebo at 12 months, P<0.001) [5]. Whether enclomiphene produces equivalent or lesser bone benefit at the testosterone levels it achieves has not been studied in men older than 65.

Monitoring Protocol for Geriatric Patients on Enclomiphene

Laboratory Schedule

| Timepoint | Tests | |---|---| | Baseline | Total T (x2, AM), free T, LH, FSH, SHBG, prolactin, hematocrit, PSA, comprehensive metabolic panel, lipid panel | | 6 weeks | Total T (AM), hematocrit | | 3 months | Total T (AM), LH, FSH, hematocrit, PSA | | 6 months | Full baseline panel repeat | | Annually | Full baseline panel, ophthalmology review if any visual complaints |

When to Discontinue

Discontinue enclomiphene and re-evaluate the patient if any of the following occur: hematocrit rises above 52%; PSA rises more than 1.4 ng/mL above baseline within any 12-month period (consistent with Endocrine Society stopping criteria for TRT [10]); new or worsening visual disturbance appears; or total testosterone exceeds 700 ng/dL on two consecutive measurements, suggesting supraphysiologic response.

Enclomiphene vs. TRT: How to Counsel Geriatric Patients

When Enclomiphene Is Preferred

Enclomiphene is a reasonable first-line option for men 65 and older who: (a) have confirmed secondary hypogonadism (LH <9 IU/L) with a baseline testosterone between 200 and 300 ng/dL; (b) wish to preserve any residual testicular function or spermatogenesis (relevant in cases of relationship changes or ethical preference); (c) have a history of erythrocytosis on prior TRT; or (d) have a contraindication to injectable or transdermal testosterone (severe skin conditions, needle phobia, or partner transfer concerns with gels).

When TRT Remains the Better Choice

Men with predominantly primary hypogonadism (LH above 12 IU/L) are unlikely to respond to enclomiphene. The Endocrine Society guideline recommends testosterone therapy for men with primary hypogonadism as standard care [10]. Men with moderate-to-severe symptomatic hypogonadism (total testosterone <150 ng/dL, severe sexual dysfunction, significant muscle loss) may need the higher and more predictable testosterone levels achievable with TRT rather than relying on a stimulatory agent.

The Shared Decision Conversation

The Endocrine Society's guideline states that clinicians "should discuss the patient's preferences, the benefits and risks of each treatment option, and set realistic expectations about the magnitude of improvement likely with therapy" [10]. For a 68-year-old man with testosterone of 265 ng/dL and mild fatigue, the conversation should include: enclomiphene may raise testosterone to 350 to 450 ng/dL (a real but modest improvement), it has not been tested in a large geriatric RCT, and response rates decline as Leydig cell reserve diminishes with age.

Regulatory Status and Insurance Coverage

Enclomiphene citrate does not hold FDA approval for any indication as of the date of this article's publication. The FDA issued a Complete Response Letter to Repros Therapeutics in 2013 and again in 2014, citing deficiencies in the clinical data package [13]. It is used off-label, compounded, or obtained through specialty pharmacy channels. Compounded enclomiphene is regulated under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Insurance rarely covers it; patients typically pay out of pocket, with costs ranging from approximately $40 to $120 per month depending on the pharmacy and dose.